265 related articles for article (PubMed ID: 32035258)
1. Development of (G3-C12)-mediated camptothecin polymeric prodrug targeting to Galectin-3 receptor against androgen-independent prostate cancer.
Yuan X; Liu L; Wang W; Gao YR; Zhang D; Jia TT; Zeng HR; Pan G; Yuan Y
Int J Pharm; 2020 Apr; 580():119123. PubMed ID: 32035258
[TBL] [Abstract][Full Text] [Related]
2. Biodegradable brush-type copolymer modified with targeting peptide as a nanoscopic platform for targeting drug delivery to treat castration-resistant prostate cancer.
Liu T; Huang Q
Int J Pharm; 2016 Sep; 511(2):1002-11. PubMed ID: 27521701
[TBL] [Abstract][Full Text] [Related]
3. Reduction-responsive amphiphilic polymeric prodrugs of camptothecin-polyphosphoester for cancer chemotherapy.
Jin H; Sun M; Shi L; Zhu X; Huang W; Yan D
Biomater Sci; 2018 May; 6(6):1403-1413. PubMed ID: 29595843
[TBL] [Abstract][Full Text] [Related]
4. Redox/pH dual-stimuli responsive camptothecin prodrug nanogels for "on-demand" drug delivery.
Qu Y; Chu B; Wei X; Lei M; Hu D; Zha R; Zhong L; Wang M; Wang F; Qian Z
J Control Release; 2019 Feb; 296():93-106. PubMed ID: 30664976
[TBL] [Abstract][Full Text] [Related]
5. Treatment of prostate carcinoma with (galectin-3)-targeted HPMA copolymer-(G3-C12)-5-Fluorouracil conjugates.
Yang Y; Zhou Z; He S; Fan T; Jin Y; Zhu X; Chen C; Zhang ZR; Huang Y
Biomaterials; 2012 Mar; 33(7):2260-71. PubMed ID: 22189143
[TBL] [Abstract][Full Text] [Related]
6. Development of octreotide-conjugated polymeric prodrug of bufalin for targeted delivery to somatostatin receptor 2 overexpressing breast cancer in vitro and in vivo.
Liu T; Jia T; Yuan X; Liu C; Sun J; Ni Z; Xu J; Wang X; Yuan Y
Int J Nanomedicine; 2016; 11():2235-50. PubMed ID: 27284243
[TBL] [Abstract][Full Text] [Related]
7. Structural Optimization and Enhanced Prodrug-Mediated Delivery Overcomes Camptothecin Resistance in High-Risk Solid Tumors.
Nguyen F; Guan P; Guerrero DT; Kolla V; Naraparaju K; Perry LM; Soberman D; Pressly BB; Alferiev IS; Chorny M; Brodeur GM
Cancer Res; 2020 Oct; 80(19):4258-4265. PubMed ID: 32839252
[TBL] [Abstract][Full Text] [Related]
8. Multifunctional Polymeric Prodrug with Simultaneous Conjugating Camptothecin and Doxorubicin for pH/Reduction Dual-Responsive Drug Delivery.
Dong S; Sun Y; Liu J; Li L; He J; Zhang M; Ni P
ACS Appl Mater Interfaces; 2019 Mar; 11(9):8740-8748. PubMed ID: 30693750
[TBL] [Abstract][Full Text] [Related]
9. Dynamic core crosslinked camptothecin prodrug micelles with reduction sensitivity and boronic acid-mediated enhanced endocytosis: An intelligent tumor-targeted delivery nanoplatform.
Huang Y; Zhang W; Xu Y; Zhu S; Wu Y; Chen T; Xiao Y; Lu W; Zhang X; Yu J
Int J Pharm; 2020 Apr; 580():119250. PubMed ID: 32209369
[TBL] [Abstract][Full Text] [Related]
10. GSH/pH dual-responsive biodegradable camptothecin polymeric prodrugs combined with doxorubicin for synergistic anticancer efficiency.
Li J; Hu ZE; Yang XL; Wu WX; Xing X; Gu B; Liu YH; Wang N; Yu XQ
Biomater Sci; 2019 Aug; 7(8):3277-3286. PubMed ID: 31180396
[TBL] [Abstract][Full Text] [Related]
11. Albumin-binding prodrugs of camptothecin and doxorubicin with an Ala-Leu-Ala-Leu-linker that are cleaved by cathepsin B: synthesis and antitumor efficacy.
Schmid B; Chung DE; Warnecke A; Fichtner I; Kratz F
Bioconjug Chem; 2007; 18(3):702-16. PubMed ID: 17378599
[TBL] [Abstract][Full Text] [Related]
12. Methotrexate-based amphiphilic prodrug nanoaggregates for co-administration of multiple therapeutics and synergistic cancer therapy.
Hou M; Gao YE; Shi X; Bai S; Ma X; Li B; Xiao B; Xue P; Kang Y; Xu Z
Acta Biomater; 2018 Sep; 77():228-239. PubMed ID: 30006314
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and optimization of a bifunctional hyaluronan-based camptothecin prodrug.
Xu Z; Zheng W; Yin Z
Arch Pharm (Weinheim); 2014 Apr; 347(4):240-6. PubMed ID: 24402828
[TBL] [Abstract][Full Text] [Related]
14. Novel SN38 conjugate-forming nanoparticles as anticancer prodrug: in vitro and in vivo studies.
Zhang H; Wang J; Mao W; Huang J; Wu X; Shen Y; Sui M
J Control Release; 2013 Mar; 166(2):147-58. PubMed ID: 23266448
[TBL] [Abstract][Full Text] [Related]
15. Rapidly cell-penetrating and reductive milieu-responsive nanoaggregates assembled from an amphiphilic folate-camptothecin prodrug for enhanced drug delivery and controlled release.
Xu Z; Hou M; Shi X; Gao YE; Xue P; Liu S; Kang Y
Biomater Sci; 2017 Feb; 5(3):444-454. PubMed ID: 28058423
[TBL] [Abstract][Full Text] [Related]
16. Increasing the anticancer performance of bufalin (BUF) by introducing an endosome-escaping polymer and tumor-targeting peptide in the design of a polymeric prodrug.
Shi XJ; Qiu YY; Yu H; Liu C; Yuan YX; Yin PH; Liu T
Colloids Surf B Biointerfaces; 2018 Jun; 166():224-234. PubMed ID: 29602078
[TBL] [Abstract][Full Text] [Related]
17. Irinotecan delivery by unimolecular micelles composed of reduction-responsive star-like polymeric prodrug with high drug loading for enhanced cancer therapy.
Gao YE; Bai S; Shi X; Hou M; Ma X; Zhang T; Xiao B; Xue P; Kang Y; Xu Z
Colloids Surf B Biointerfaces; 2018 Oct; 170():488-496. PubMed ID: 29960949
[TBL] [Abstract][Full Text] [Related]
18. pH-sensitive prodrug conjugated polydopamine for NIR-triggered synergistic chemo-photothermal therapy.
Zhang H; Sun Y; Huang R; Cang H; Cai Z; Sun B
Eur J Pharm Biopharm; 2018 Jul; 128():260-271. PubMed ID: 29733952
[TBL] [Abstract][Full Text] [Related]
19. Two birds, one stone: dual targeting of the cancer cell surface and subcellular mitochondria by the galectin-3-binding peptide G3-C12.
Sun W; Li L; Li LJ; Yang QQ; Zhang ZR; Huang Y
Acta Pharmacol Sin; 2017 Jun; 38(6):806-822. PubMed ID: 28065935
[TBL] [Abstract][Full Text] [Related]
20. Redox-sensitive lipophilic prodrugs: delivering unstable chemotherapeutant for improved cancer therapy.
Li F; Huang Z; Chen H; Yan L; Li J; Su Y; Zhang Q; Huang Z; Zheng Y
Drug Deliv; 2019 Dec; 26(1):1068-1079. PubMed ID: 31735094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
